Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-35 in Healthy Volunteers
NCT05116969Phase 1Withdrawn
- Sponsor
- NightHawk Biosciences, Inc.
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of PTX-35 in solid tumor (7 arms), sponsored by NightHawk Biosciences, Inc. Primary endpoint: Safety and Tolerability (Primary) up to 60 days. Planned start Nov 2021; status: withdrawn.
02
Drugs
PTX-35
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05116969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116969.